These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8036014)

  • 1. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts.
    Gardner HA; Berse B; Senger DR
    Oncogene; 1994 Aug; 9(8):2321-6. PubMed ID: 8036014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of antisense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of mouse JB6 epidermal cells.
    Su L; Mukherjee AB; Mukherjee BB
    Oncogene; 1995 Jun; 10(11):2163-9. PubMed ID: 7784060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA.
    Behrend EI; Craig AM; Wilson SM; Denhardt DT; Chambers AF
    Cancer Res; 1994 Feb; 54(3):832-7. PubMed ID: 8306346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming JB6 cells exhibit enhanced integrin-mediated adhesion to osteopontin.
    Chang PL; Chambers AF
    J Cell Biochem; 2000 Apr; 78(1):8-23. PubMed ID: 10797562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells.
    Chambers AF; Behrend EI; Wilson SM; Denhardt DT
    Anticancer Res; 1992; 12(1):43-7. PubMed ID: 1567180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells.
    Tuck AB; Arsenault DM; O'Malley FP; Hota C; Ling MC; Wilson SM; Chambers AF
    Oncogene; 1999 Jul; 18(29):4237-46. PubMed ID: 10435636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration.
    Zohar R; Suzuki N; Suzuki K; Arora P; Glogauer M; McCulloch CA; Sodek J
    J Cell Physiol; 2000 Jul; 184(1):118-30. PubMed ID: 10825241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells.
    Mi Z; Guo H; Wai PY; Gao C; Kuo PC
    Carcinogenesis; 2006 Jun; 27(6):1134-45. PubMed ID: 16474180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation.
    Senger DR; Perruzzi CA; Papadopoulos A
    Anticancer Res; 1989; 9(5):1291-9. PubMed ID: 2686530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells.
    Shanmugam V; Chackalaparampil I; Kundu GC; Mukherjee AB; Mukherjee BB
    Biochemistry; 1997 May; 36(19):5729-38. PubMed ID: 9153413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells.
    Su ZZ; Austin VN; Zimmer SG; Fisher PB
    Oncogene; 1993 May; 8(5):1211-9. PubMed ID: 8479744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12.
    Teramoto H; Castellone MD; Malek RL; Letwin N; Frank B; Gutkind JS; Lee NH
    Oncogene; 2005 Jan; 24(3):489-501. PubMed ID: 15516973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin.
    Furger KA; Allan AL; Wilson SM; Hota C; Vantyghem SA; Postenka CO; Al-Katib W; Chambers AF; Tuck AB
    Mol Cancer Res; 2003 Sep; 1(11):810-9. PubMed ID: 14517343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions.
    Xuan JW; Hota C; Shigeyama Y; D'Errico JA; Somerman MJ; Chambers AF
    J Cell Biochem; 1995 Apr; 57(4):680-90. PubMed ID: 7542253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteopontin is a negative regulator of proliferation and differentiation in MC3T3-E1 pre-osteoblastic cells.
    Huang W; Carlsen B; Rudkin G; Berry M; Ishida K; Yamaguchi DT; Miller TA
    Bone; 2004 May; 34(5):799-808. PubMed ID: 15121011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells.
    Chang PL; Cao M; Hicks P
    Carcinogenesis; 2003 Nov; 24(11):1749-58. PubMed ID: 12919959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity of osteopontin expression among nephrons in mouse kidneys and enhanced expression in sclerotic glomeruli.
    Lopez CA; Hoyer JR; Wilson PD; Waterhouse P; Denhardt DT
    Lab Invest; 1993 Sep; 69(3):355-63. PubMed ID: 8377476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model.
    Oates AJ; Barraclough R; Rudland PS
    Oncogene; 1996 Jul; 13(1):97-104. PubMed ID: 8700559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer.
    Sharp JA; Sung V; Slavin J; Thompson EW; Henderson MA
    Lab Invest; 1999 Jul; 79(7):869-77. PubMed ID: 10418827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of osteopontin in tumorigenesis and metastasis.
    Oates AJ; Barraclough R; Rudland PS
    Invasion Metastasis; 1997; 17(1):1-15. PubMed ID: 9425320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.